Tenofovir (Viread): Research
- The Path to a Cure (January/February 2012)
The pathway to an HIV cure and other treatments in the pipeline.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Pivotal HIV Prevention Trial for Women in Africa Finds That Use of Tenofovir Gel Does Not Prevent HIV: What Does This Mean for HIV Prevention for Women? (November 28, 2011)
Global Campaign for Microbicides statement on the VOICE DSMB decision to discontinue use of tenofovir gel.
From Global Campaign for Microbicides
- NIH Discontinues Tenofovir Vaginal Gel in "VOICE" HIV Prevention Study (November 25, 2011)
Product safe but no more effective than placebo.
From U.S. National Institutes of Health
- VOICE Trial Changes Are Disappointing, Says AVAC; Calls for Continued Research to Find New Prevention Options for Women (November 25, 2011)
To read PDF, click here.
From AIDS Vaccine Advocacy Coalition
- NIH Researchers Show How Anti-HIV Drug Acts to Block Herpes Virus (October 20, 2011)
Newfound effectiveness of tenofovir due to higher concentrations in vaginal gel form.
From U.S. National Institutes of Health
- EuroSIDA Study Finds a Signal of Kidney Toxicity With Tenofovir or Atazanavir (June 30, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- EuroSIDA Study Suggests Tenofovir Increases Risk of Chronic Kidney Disease (February 21, 2010)
From aidsmap.com
- Antiretroviral Risk Factors for Kidney Disease in EuroSIDA: Tenofovir Is Not Alone (February 19, 2010)
From National AIDS Treatment Advocacy Project
- Tenofovir and the Kidneys (February 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
- Tenofovir/Emtricitabine Performs Better Than Abacavir/Lamivudine in Subgroup of Antiretroviral-Naive, HIV-Infected Individuals (December 1, 2009)
From National Institute of Allergy and Infectious Diseases
On TheBodyPRO.com
- Serious Non-AIDS Health Problems (Especially Heart Problems) Appear Less Likely With Truvada Than Epzicom, But Low Bone Mineral Density Is More Likely, Switch Study Finds (October 20, 2009)
In Clinical Infectious Diseases
- Study Suggests Some People With Kidney Trouble Can Start Viread Anyway (September 15, 2009)
From International AIDS Society
- A Large Study Looks at Tenofovir and Kidney Health (July/August 2009)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Age, Tenofovir and the Kidneys (July/August 2009)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV (April 17, 2009)
Study will assess safety and efficacy of single-tablet regimen containing elvitegravir boosted by GS 9350 and Truvada compared to Atripla.
From Gilead Sciences, Inc.
On TheBodyPRO.com
- Topical PrEP Comparison: Tenofovir Alone May Be as Effective as Tenofovir/FTC, Study Finds (February 9, 2009)
Walid Heneine, Ph.D., explains the results of a study in macaques which found that a topical gel offered complete protection against SIV infection -- regardless of whether that gel contained tenofovir alone or tenofovir in combination with emtricitabine.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
- Tenofovir Shows Excellent Promise as a Treatment for Hepatitis B Monoinfection (April 25, 2008)
From aidsmap.com
- Major Study Finds Red Flags When Using Epzicom as First-Line Therapy in People With High Viral Load (February 28, 2008)
Combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naive individuals.
From U.S. National Institute of Allergy and Infectious Diseases
On TheBodyPRO.com
- Tenofovir Appears Effective Against HIV and Hepatitis B in Coinfected People (June 12, 2007)
From aidsmap.com
|
Advertisement
|
Email
Glossary
